scholarly journals A qualitative study of online support communities for lung cancer survivors on targeted therapies

2021 ◽  
Author(s):  
Casey A. Walsh ◽  
Morhaf Al Achkar
Keyword(s):  
Lung Cancer ◽  
Qualitative Study ◽  
Cancer Survivors ◽  
Targeted Therapies ◽  
Online Support

Enhancing behavioral change among lung cancer survivors participating in a lifestyle risk reduction intervention: a qualitative study

2019 ◽  
Vol 27 (4) ◽  
pp. 1299-1308
Author(s):  
Darryl Somayaji ◽  
Amanda C. Blok ◽  
Laura L. Hayman ◽  
Yolanda Colson ◽  
Michael Jaklisch ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Qualitative Study ◽  
Cancer Survivors ◽  
Risk Reduction ◽  
Behavioral Change ◽  
Lifestyle Risk ◽  
Risk Reduction Intervention ◽  
Lifestyle Risk Reduction

scholarly journals In their own words: A qualitative study of the psychosocial concerns of posttreatment and long-term lung cancer survivors

2016 ◽  
Vol 34 (3) ◽  
pp. 169-183 ◽  
Author(s):  
Elizabeth A. Rohan ◽  
Jennifer Boehm ◽  
Kristine Gabuten Allen ◽  
Jon Poehlman
Keyword(s):  
Lung Cancer ◽  
Qualitative Study ◽  
Cancer Survivors ◽  
Psychosocial Concerns

Follow-Up Care Lacking for Lung Cancer Survivors

2008 ◽  
Vol 41 (9) ◽  
pp. 20
Author(s):  
FRAN LOWRY
Keyword(s):  
Lung Cancer ◽  
Cancer Survivors ◽  
Follow Up Care

scholarly journals The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments

Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 3923
Author(s):  
Daniel Di Capua ◽  
Dara Bracken-Clarke ◽  
Karine Ronan ◽  
Anne-Marie Baird ◽  
Stephen Finn
Keyword(s):  
Lung Cancer ◽  
Lung Carcinoma ◽  
Targeted Therapies ◽  
Liquid Biopsy ◽  
Genetic Alterations ◽  
Rapid Progression ◽  
Liquid Biopsies ◽  
Cell Lung Carcinoma ◽  
Genetic Sequencing ◽  
Tissue Biopsy

Lung cancer is a leading cause of cancer-related deaths, contributing to 18.4% of cancer deaths globally. Treatment of non-small cell lung carcinoma has seen rapid progression with targeted therapies tailored to specific genetic drivers. However, identifying genetic alterations can be difficult due to lack of tissue, inaccessible tumors and the risk of complications for the patient with serial tissue sampling. The liquid biopsy provides a minimally invasive method which can obtain circulating biomarkers shed from the tumor and could be a safer alternative to tissue biopsy. While tissue biopsy remains the gold standard, liquid biopsies could be very beneficial where serial sampling is required, such as monitoring disease progression or development of resistance mutations to current targeted therapies. Liquid biopsies also have a potential role in identifying patients at risk of relapse post treatment and as a component of future lung cancer screening protocols. Rapid developments have led to multiple platforms for isolating circulating tumor cells (CTCs) and detecting circulating tumor DNA (ctDNA); however, standardization is lacking, especially in lung carcinoma. Additionally, clonal hematopoiesis of uncertain clinical significance must be taken into consideration in genetic sequencing, as it introduces the potential for false positives. Various biomarkers have been investigated in liquid biopsies; however, in this review, we will concentrate on the current use of ctDNA and CTCs, focusing on the clinical relevance, current and possible future applications and limitations of each.

scholarly journals Comprehensive Perspective for Lung Cancer Characterisation Based on AI Solutions Using CT Images

2020 ◽  
Vol 10 (1) ◽  
pp. 118
Author(s):  
Tania Pereira ◽  
Cláudia Freitas ◽  
José Luis Costa ◽  
Joana Morgado ◽  
Francisco Silva ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapies ◽  
Treatment Plan ◽  
Personalised Medicine ◽  
Growth Factor Receptor ◽  
Accurate Diagnosis ◽  
Cancer Development ◽  
Thoracic Computed Tomography ◽  
Plan Selection ◽  
Ct Image Analysis

Lung cancer is still the leading cause of cancer death in the world. For this reason, novel approaches for early and more accurate diagnosis are needed. Computer-aided decision (CAD) can be an interesting option for a noninvasive tumour characterisation based on thoracic computed tomography (CT) image analysis. Until now, radiomics have been focused on tumour features analysis, and have not considered the information on other lung structures that can have relevant features for tumour genotype classification, especially for epidermal growth factor receptor (EGFR), which is the mutation with the most successful targeted therapies. With this perspective paper, we aim to explore a comprehensive analysis of the need to combine the information from tumours with other lung structures for the next generation of CADs, which could create a high impact on targeted therapies and personalised medicine. The forthcoming artificial intelligence (AI)-based approaches for lung cancer assessment should be able to make a holistic analysis, capturing information from pathological processes involved in cancer development. The powerful and interpretable AI models allow us to identify novel biomarkers of cancer development, contributing to new insights about the pathological processes, and making a more accurate diagnosis to help in the treatment plan selection.

scholarly journals A qualitative study on the experience of empowerment from the perspectives of breast cancer survivors

Nursing Open ◽  
2021 ◽  
Author(s):  
Zebing Luo ◽  
Chujun Chen ◽  
Wanzhu Xu ◽  
Peiru Wang ◽  
Yiru Wang
Keyword(s):  
Breast Cancer ◽  
Qualitative Study ◽  
Cancer Survivors ◽  
Breast Cancer Survivors

scholarly journals SURG-05. IDEAL TREATMENT REGIMEN FOR PATIENTS WITH ≥1 BRAIN METASTASIS FROM PRIMARY NON-SMALL-CELL LUNG CANCER – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii204-ii204
Author(s):  
Karanbir Brar ◽  
Yosef Ellenbogen ◽  
Behnam Sadeghirad ◽  
Jiawen Deng ◽  
Winston Hou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Targeted Therapies ◽  
Meta Analysis ◽  
Performance Status ◽  
Progression Free Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
China National Knowledge Infrastructure

Abstract BACKGROUND Brain metastases (BM) are common in non-small cell lung cancer (NSCLC). The aim of this study was to assess the comparative effectiveness of treatments for BM from NSCLC. METHODS We searched MEDLINE, EMBASE, Web of Science, ClinicalTrials.gov, CENTRAL and references of key studies for randomized controlled trials (RCTs) published until October 2018. We also searched the Chinese databases Wanfang Data, Wanfang Med Online, China National Knowledge Infrastructure, and Chongqing VIP Information for RCTs published until September 2019. Trials including > 10 patients were selected. The primary outcomes were overall survival (OS) and intracranial progression-free survival (PFS). We used a frequentist random-effects model for network meta-analysis and assessed the certainty of evidence using the GRADE approach. RESULTS Among 8798 abstracts, 106 RCTs (9452 patients) met inclusion criteria. Median sample size was 67 (range 25-554). All trials included adult patients with histologically proven NSCLC and >1 BM proven on CT/MRI. Of trials that reported performance status (e.g. ECOG or KPS, n=67), 63/67 excluded patients with non-favorable performance status. Interventions assessed included surgery, WBRT, SRS, targeted therapies (i.e. EGFR/ALK inhibitors), and chemotherapy. Compared to WBRT alone, several interventions demonstrated a statistically significant increase in median OS, including non-targeted chemotherapy + surgery (MD: 415.3 days, 95% CI: 31.3-799.4), WBRT + EGFRi (MD: 200.2 days, 95% CI:146.3-254.1), and EGFRi alone (MD: 169.7 days, 95% CI: 49.7-289.7). Among all interventions, only WBRT + EGFRi showed a significant improvement in median PFS (MD: 108.0 days, 95%CI: 48.5-167.5). CONCLUSIONS Our preliminary analyses indicate an OS and PFS benefit on the addition of EGFR inhibitors to WBRT for the treatment of BMs from NSCLC. Further analyses of hazard ratios for OS/PFS are underway, and subgroup analyses are planned. These data support the growing role of targeted therapies in the treatment of BMs, particularly in susceptible mutant tumours.

scholarly journals A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker

2020 ◽  
Vol 28 (1) ◽  
pp. 196-202
Author(s):  
Alla Turshudzhyan ◽  
James Vredenburgh
Keyword(s):  
Lung Cancer ◽  
Targeted Therapies ◽  
Kinase Activity ◽  
Mitogen Activated Protein Kinase ◽  
Braf Mutations ◽  
Activating Mutations ◽  
Extracellular Signal ◽  
Activating Mutation ◽  
Mitogen Activated Protein ◽  
Murine Sarcoma

V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) mutated non-small-cell lung cancer (NSCLC) is an exceptionally rare form of lung cancer, found only in one to two percent of patients with an NSCLC diagnosis. BRAF NSCLC traditionally affects former or active smokers. BRAF mutations have always been of special interest to the oncological community, as they offer potential for targeted therapies. BRAF mutation spectrum includes mutations that are of both V600 and non-V600 types. BRAF V600 is an activating mutation, which results in high kinase activity and overproduction of active oncoproteins such as rapidly accelerated fibrosarcoma (RAF). This makes them susceptible to targeted therapies with RAF inhibitors. There has been little evidence, however, regarding efficacy of RAF inhibitors towards non-activating mutations that have intermediate to low kinase activity, such as non-V600 BRAF mutations. While several approaches have been investigated to overcome the limitations of RAF inhibitors, such as use of mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) inhibitors or combination of MEK and RAF inhibitors, none of them have been proven to have a superior efficacy for low kinase activity non-V600 BRAF tumors. We present a case of an extremely rare variant of NSCLC BRAF p.T599dup mutation in a non-smoker that responded to a targeted combination therapy with RAF and MEK inhibitors. The patient responded well to therapy that usually targets high kinase activity V600 mutations. Our hope is to bring more attention to non-V600 mutations and document their responses to existing and new therapies.

Sign in / Sign up

Export Citation Format

Share Document